Cellectar Biosciences has closed its $103 million private placement financing, the company announced today.

According to a release, the financing was led by Rosalind Advisors with participation from AIGH Capital, ADAR1, Second Line, Nantahala Capital, AuGC and other new and existing institutional investors.

The biotech company expects to release top-line data from its WM CLOVER-WaM pivotal trial in the second half of 2023 and remains on target for a 2024 product launch.